Gastric GIST malignancy evaluated by ¹⁸FDG-PET as compared with EUS-FNA and endoscopic biopsy

References

• Kitamura Y, Hirota S, Nishida T. Molecular pathology of c-kitproto-oncogene and development of gastrointestinal stromal tumors. Ann Chir Gynaecol 1998; 87: 282–6
   PubMedGoogle Scholar
• Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–80
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12
   PubMed Web of Science ®Google Scholar
• Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41–7
   PubMed Web of Science ®Google Scholar
• Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji M. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992; 69: 947–55
   PubMed Web of Science ®Google Scholar
• DeMettero RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence and prognostic factors for survival. Ann Surg 2000; 231: 51–8
   PubMed Web of Science ®Google Scholar
• Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660–7
   PubMed Web of Science ®Google Scholar
• Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005; 11: 638–45
   PubMed Web of Science ®Google Scholar
• Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566–78
   PubMed Web of Science ®Google Scholar
• Matsui M, Goto H, Niwa Y, Arisawa T, Hirooka Y, Hayakawa T. Preliminary results of fine aspiration biopsy histology in upper gastrointestinal submucosal tumors. Endoscopy 1998; 30: 750–5
   PubMed Web of Science ®Google Scholar
• Kameyama H, Niwa Y, Arisawa T, Goto H, Hayakawa T. Endoscopic ultrasonography in the diagnosis of submucosal lesions of the large intestine. Gastrointest Endosc 1997; 46: 406–11
   PubMed Web of Science ®Google Scholar
• Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T, et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002; 55: 37–43
   PubMed Web of Science ®Google Scholar
• Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34: 414–19
   PubMed Web of Science ®Google Scholar
• Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776–81
   PubMed Web of Science ®Google Scholar
• Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F–18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6: 1279–87
   PubMed Web of Science ®Google Scholar
• Annovazzi A, Peeters M, Maenhout A, Signore A, Dierckx R, Van De Wiele C. 18-Fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003; 125: 1235–45
   PubMed Web of Science ®Google Scholar
• Chin BB, Wahl RL. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 2003; 52: 23–9
   Web of Science ®Google Scholar
• Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012–20
   PubMed Web of Science ®Google Scholar
• Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17–21
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004; 183: 1619–28
   PubMed Web of Science ®Google Scholar
• Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005; 29: 1429–35
   PubMed Web of Science ®Google Scholar
• Goldblum JR, Appelman HD. Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. Am J Surg Pathol 1995; 19: 71–80
   PubMed Web of Science ®Google Scholar
• Brainard JA, Goldblum JR. Stromal tumors of jejunum and ileum: a clinicopathologic study of 39 cases. Am J Surg Pathol 1997; 21: 407–16
   PubMed Web of Science ®Google Scholar
• Tworek JA, Appelman HD, Singleton TP, Greenson JK. Stromal tumors of jejunum and ileum. Mod Pathol 1997; 10: 200–9
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24: 1339–52
   PubMed Web of Science ®Google Scholar
• Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25: 1121–33
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459–65
   PubMed Web of Science ®Google Scholar
• Nilsson B, Bumming P, Meis-Kindblom, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103: 821–9
   PubMed Web of Science ®Google Scholar
• Weber G. Enzymology of cancer cells (second part). N Engl J Med 1977; 296: 541–51
   PubMed Web of Science ®Google Scholar
• Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82–7
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Isozaki K, Tsutsui S, Kitamura S, Hiraoka S, Watabe K, et al. Endoscopic ultrasonography-guided fine needle aspiration biopsy in follow-up patients with gastrointestinal stromal tumours. Eur J Gastro Hepatol 2003; 15: 1189–93
   PubMed Web of Science ®Google Scholar